JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeNardo, S. J.
Right arrow Articles by Ivkov, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeNardo, S. J.
Right arrow Articles by Ivkov, R.

Thermal Dosimetry Predictive of Efficacy of 111In-ChL6 Nanoparticle AMF–Induced Thermoablative Therapy for Human Breast Cancer in Mice

Sally J. DeNardo1, Gerald L. DeNardo1, Arutselvan Natarajan1, Laird A. Miers1, Allan R. Foreman2, Cordula Gruettner3, Grete N. Adamson1 and Robert Ivkov2

1 School of Medicine, University of California Davis, Sacramento, California; 2 Triton BioSystems, Inc., Chelmsford, Massachusetts; and 3 Micromod Partikeltechnologie, GmbH, Rostock-Warnemuende, Germany


Figure 1
View larger version (70K):
[in this window]
[in a new window]

  		FIGURE 1.  Schematic of a bioprobe: 111In-ChL6 conjugated to PEG on iron oxide–impregnated dextran 20-nm nanoparticles.

 

Figure 2
View larger version (37K):
[in this window]
[in a new window]

  		FIGURE 2.  AMF delivery coil used to treat mice bearing human xenograft tumors. AMF is focused in a 1-cm band in which subcutaneous tumor located on abdomen of each mouse was positioned. Major components of the system are (a) induction coil, (b) capacitance network, and (c) power supply (17).

 

Figure 3
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 3.  Pharmacokinetics of 111In-ChL6 bioprobes in mice with HBT3477 human breast cancer xenografts. (A) Blood clearance of 111In-ChL6 bioprobes (•) was more rapid than that of 111In-ChL6 mAb alone ({circ}). Whole-body clearances ({blacksquare}, {square}) were similar. (B) Concentrations (%ID/g) of 111In-ChL6 bioprobes in blood, tumor, liver, lung, kidneys, spleen, and marrow at 1 d (Figure 3), 2 d (Figure 3), 3 d (Figure 3), and 4 d (Figure 3) after injection. Maximum concentrations in liver and spleen were almost twice and tumor concentration was about 75% of that previously observed for 111In-ChL6 mAb (16). Concentrations of 111In in other normal tissues were similar to those of 111In-ChL6 mAb.

 

Figure 4
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 4.  Relationship of tumor response to bioprobe AMF Rx. Therapeutic response is reflected by increased time to double, triple, and quadruple tumor volume in mice receiving higher THDs (J). A statistical relationship between response and THD was demonstrated for tumors receiving 13–19 and 21 J/g compared with that of controls (Table 3). Tumor growths of AMF alone, bioprobes alone, and untreated control groups of mice were statistically indistinguishable, so they were grouped as controls.

 

Figure 5
View larger version (74K):
[in this window]
[in a new window]

  		FIGURE 5.  Electron micrographs of ultrathin osmium tetroxide–fixed epoxy-embedded HBT3477 xenografts that had been excised from mice at time of sacrifice: (A) 48 h after bioprobes, no AMF; (B) 24 h after AMF Rx (18 J/g); and (C) 48 h after AMF Rx (18 J/g). Healthy cells (A) contrast with evidence for cell necrosis at 24 h after AMF Rx (B) and further evidence for necrosis 48 h after AMF Rx (C).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.